Federated Hermes
NPCE icon

Federated Hermes’s Neuropace NPCE Stock Holding History

Federated Hermes’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-226
Closed -$2.98K – 2104
2024
Q1 		$2.98K Buy
226
+110
+95% +$1.57K ﹤0.01% 1883
2023
Q4 		$1.2K Sell
116
-308
-73% -$2.46K ﹤0.01% 1965
2023
Q3 		$4.13K Buy
+424
New +$2.48K ﹤0.01% 1907

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federated Hermes's NPCE Position: Q2 2024 in Review

Federated Hermes sold out of Neuropace (NPCE) in Q2 2024, closing a stake of 226 shares — an estimated $2.98K sold.

Federated Hermes first reported a position in NPCE in Q3 2023 and held it in 3 quarters. The position peaked at $4.13K in Q3 2023. 51 funds tracked by Wall St. Rank hold NPCE as of Q2 2024.

  • Federated Hermes reported no remaining Neuropace position as of Q2 2024 after selling out during the quarter.
  • Federated Hermes sold 226 Neuropace shares in Q2 2024, an estimated $2.98K.
  • Federated Hermes first reported a position in Neuropace in Q3 2023 and held it in 3 quarters.
  • Federated Hermes's Neuropace position peaked at $4.13K in Q3 2023.
  • 51 funds tracked by Wall St. Rank held Neuropace as of Q2 2024.

Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.